References
- McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001; 41: 101–121.
- Sekine I, Saijo N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 2001; 12: 1515–25.
- Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003; 17: 27–41.
- van't Veer II, de Jong D. The microarray way to tai-lored cancer treatment. Nature Med 2002; 8: 13–4.
- Clarke PA, Poele RT, Wooster R, Workman P. Gene expression microarray analysis in cancer biology, pharmacolo-gy, and drug development: progress and potential. Biochem Pharmacol 2001; 62: 1311–1336.
- Friedrich MJ. Gene profiles may help predict response to chemotherapy. J Natl Cancer Inst 2002; 94: 1052–3.
- Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al. A gene expression database for the molecu-lar pharmacology of cancer. Nat Genet 2000; 24: 236–244.
- Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J. Molecular determinants of the cytotoxicity of plat-inum compounds: the contribution of in silico research. Cancer Res 2004; 64: 356–62.